Jazz Pharmaceuticals PLC (JAZZ): Today's Featured Health Care Laggard

Jazz Pharmaceuticals ( JAZZ) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole was unchanged today. By the end of trading, Jazz Pharmaceuticals fell 74 cents (-1.6%) to $46.71 on average volume. Throughout the day, 662,412 shares of Jazz Pharmaceuticals exchanged hands as compared to its average daily volume of 789,200 shares. The stock ranged in price between $46-$47.93 after having opened the day at $47.83 as compared to the previous trading day's close of $47.45. Other companies within the Health Care sector that declined today were: Response Genetics ( RGDX), down 19.4%, Escalon Medical Corporation ( ESMC), down 17.4%, Tengion ( TNGN), down 15.2%, and Senesco Technologies ( SNT), down 12.9%.

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, focuses on the identification, development, and commercialization of pharmaceutical products to meet unmet medical needs. Jazz Pharmaceuticals has a market cap of $2.66 billion and is part of the drugs industry. The company has a P/E ratio of 19.7, above the average drugs industry P/E ratio of 17.5 and above the S&P 500 P/E ratio of 17.7. Shares are up 22.3% year to date as of the close of trading on Monday. Currently there are six analysts that rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Jazz Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, compelling growth in net income, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the positive front, ERBA Diagnostics ( ERB), up 27.9%, AEterna Zentaris ( AEZS), up 19.4%, Cormedix ( CRMD), up 14.8%, and Arena Pharmaceuticals ( ARNA), up 14.1%, were all gainers within the health care sector with Gilead ( GILD) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).